Effective Desensitization Protocol to Paclitaxel Following Hypersensitivity Reaction
作者： A. FISHMAN , T. GOLD , A. GOLDBERG , R. CONFINO-COHEN , Y. BEYTH
DOI: 10.1046/J.1525-1438.1999.99014.X
关键词:
摘要: The objective of this paper is to describe our experience with a desensitization protocol paclitaxel using the original solution in patients following severe hypersensitivity reactions. A retrospective review 75 consecutive ovarian cancer who received intravenous paclitaxel-based chemotherapy between January 1996 and May 1998 at Gynecologic Oncology Unit Meir Hospital-Sapir Medical Center, Kfar-Saba, Israel. All developed reaction were treated protocol. included serial 10-fold dilutions (up 1:100,000) actual infusate, delivered successive volumes 1, 2, 4, 8 ml. These escalating doses given intravenously 15-min intervals for each dilution. Following administration last diluted dose, patient 1-ml dose undiluted solution. If no side effects recorded, rest was 3-h infusion rate. Vital signs monitored recorded throughout course treatment. Six previous paclitaxel-associated successfully In conclusion, we demonstrate that feasible safe without compromising cytotoxic activity. Our results show strategy reasonable choice clinical setting potentially avoids regimen interruption.
sci-hub.se 参考文章(12)
William P. McGuire, William J. Hoskins, Mark F. Brady, Paul R. Kucera, Edward E. Partridge, Katherine Y. Look, Daniel L. Clarke-Pearson, Martin Davidson, Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer The New England Journal of Medicine. ,vol. 334, pp. 1- 6 ,(1996) , 10.1056/NEJM199601043340101
Kevin J. Hunt, Martin D. Valentine, Anne K. Sobotka, Allen W. Benton, Frank J. Amodio, Lawrence M. Lichtenstein, A Controlled Trial of Immunotherapy in Insect Hypersensitivity New England Journal of Medicine. ,vol. 299, pp. 157- 161 ,(1978) , 10.1056/NEJM197807272990401
D M Peereboom, R C Donehower, E A Eisenhauer, W P McGuire, N Onetto, J L Hubbard, M Piccart, L Gianni, E K Rowinsky, Successful re-treatment with taxol after major hypersensitivity reactions. Journal of Clinical Oncology. ,vol. 11, pp. 885- 890 ,(1993) , 10.1200/JCO.1993.11.5.885
M S Laskin, K J Lucchesi, M Morgan, Paclitaxel rechallenge failure after a major hypersensitivity reaction. Journal of Clinical Oncology. ,vol. 11, pp. 2456- 2457 ,(1993) , 10.1200/JCO.1993.11.12.2456
R B Weiss, R C Donehower, P H Wiernik, T Ohnuma, R J Gralla, D L Trump, J R Baker, D A Van Echo, D D Von Hoff, B Leyland-Jones, Hypersensitivity reactions from taxol. Journal of Clinical Oncology. ,vol. 8, pp. 1263- 1268 ,(1990) , 10.1200/JCO.1990.8.7.1263
Maurie Markman, The administration of paclitaxel without prophylaxis for the prevention of hypersensitivity reactions: is this a rationale and safe therapeutic strategy? Journal of Cancer Research and Clinical Oncology. ,vol. 123, pp. 531- 532 ,(1997) , 10.1007/S004320050100
Giuseppe Del Priore, Pamela Smith, David P. Warshal, Brent Dubeshter, Cynthia Angel, Paclitaxel-Associated Hypersensitivity Reaction despite High-Dose Steroids and Prolonged Infusions Gynecologic Oncology. ,vol. 56, pp. 316- 318 ,(1995) , 10.1006/GYNO.1995.1054
David M. Essayan, Anne Kagey-Sobotka, Patrick J. Colarusso, Lawrence M. Lichtenstein, Robert F. Ozols, Earl D. King, Successful parenteral desensitization to paclitaxel The Journal of Allergy and Clinical Immunology. ,vol. 97, pp. 42- 46 ,(1996) , 10.1016/S0091-6749(96)70281-6
M.A. Bookman, D.D. Kloth, P.E. Kover, S. Smolinski, R.F. Ozols, Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions Annals of Oncology. ,vol. 8, pp. 611- 614 ,(1997) , 10.1023/A:1008207025430
Janos Szebeni, Carl R. Alving, Franco M. Muggia, Complement Activation by Cremophor EL as a Possible Contributor to Hypersensitivity to Paclitaxel: an In Vitro Study Journal of the National Cancer Institute. ,vol. 90, pp. 300- 306 ,(1998) , 10.1093/JNCI/90.4.300